In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Device/Diagnostics Quarterly Deal Statistics, Q2 2014

Executive Summary

Device funding increased 123% to $1.6 billion in Q2, and M&A activity was overshadowed by Medtronic’s massive $47 billion acquisition of Covidien. Diagnostics fundraising dropped slightly to $522 million, and there were multiple takeovers of life sciences companies.

You may also be interested in...

Medtech Buyers Mull Mega-Mergers, Earn-Outs, And Google

Even with a surge in IPO opportunities, M&A remains the primary – almost exclusive – exit route for medtech investors and entrepreneurs. A panel of business development professionals speaking at the recent IN3 360° Boston conference presented insights on how start-ups might improve their chances of being acquired.

K2M Funds Its Focus On The Complex Spine With IPO

The 10-year-old spine firm initiated its initial public offering this month, transforming from the largest private spine device firm to another public player in a highly competitive market. CEO Eric Major says K2M’s focus on complex spinal deformities will help distinguish it from the pack.

More Mergers As A Direct Result Of Medtronic-Covidien Combo? Mixed Prospects

Medtronic’s massive acquisition of Covidien could accelerate the trend of industry consolidation further, some say. But executives from several big device firms insist nothing fundamental has changed.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts